Undersøgelse af PHN131 hos patienter efter operation
En randomiseret, dobbeltblind, placebo-kontrolleret, multiple dosis undersøgelse for at vurdere effektivitet, sikkerhed og farmakokinetik af oral nalbuphin, en oral blød kapsel, til post-hæmorrhoidektomi smertebehandling
The purpose of this study is to assess the effectiveness, safety and pharmacokinetics of Oral Nalbuphine in the treatment of postoperative pain following hemorrhoidectomy.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
• Primary Efficacy Endpoint: Pain assessment calculated as the area under the curve of VAS pain intensity scores through 48 hours.
• Secondary Efficacy Endpoints:
- Consumption of diclofenac (Day 1-2) via Intramuscular Injection (IM injection).
- Time from the end of operation to the first IM injection diclofenac dose
- Brief Pain Inventory (BPI).
- Patient satisfaction.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Taipei, Taiwan, 114
- General Clinical Research Center, Tri-service General Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female >= 20 years of age at Screening
- Scheduled to electively undergo 2 or 3-column excisional hemorrhoidectomy
- American Society of Anesthesiology Physical Class 1 - 3
- Clinical lab values twice the upper limit of normal (values of potential clinical concern are detailed in Appendix) or, if abnormal, deemed not clinically significant per the Investigator.
- Ability and willingness to provide informed consent, adhere to the study visit schedule and complete all study assessments and language specific questionnaires.
Exclusion Criteria:
- Body weight less than 40 kg.
- Concurrent fissurectomy.
- Subject is pregnant or breastfeeding. Women of childbearing potential must have a negative urine pregnancy test at Baseline.
- Women of childbearing potential disagree to use an acceptable method of contraception (e.g., hormonal contraceptives, Intrauterine Device (IUD), barrier device or abstinence) throughout the study.
- History of hypersensitivity or allergy to amide-type local anesthetics, opioid, or any ingredient of the medications administered in this study.
- Subject has a resting respiratory rate less than 8 per minute and blood oxygen saturation less than 90 mmHg.
- Use of any NSAIDs, selective Cyclooxygenase-2 Inhibitors, opioid, acetaminophen, selective serotonin reuptake inhibitors (SSRI), tricyclic antidepressants (TCA), gabapentin, or pregabalin within three days of surgery.
- Chronic use of opioid medications for more than 14 days in the last 3 months, or non-opioid pain medications more than 5 times per week.
- Use of any long-acting opioid medication within 3 days of surgery or any opioid medication within 24 hours of surgery.
- Current painful physical condition or concurrent surgery requires analgesic treatment in the postoperative period.
- Contraindication to epinephrine or any of the pain-control agents planned for postoperative use.
- Administration of an investigational drug within the longer of 30 days or 5 elimination half-lives of such investigational drug prior to study drug administration.
- Any psychiatric disorder, psychological, medical, or laboratory condition that may interfere with study assessments or compliance.
- Significant medical conditions or laboratory results that may indicate an increased vulnerability to study drugs and procedures, and thus expose the subject to an unreasonable risk as a result of participating in this clinical trial.
- Any clinically significant event or condition uncovered during surgery.
- History of abuse illicit drugs, prescription medicines or alcohol within the past 2 years.
- Known history of anti-HIV antibody positive .
- Failure to pass drug and alcohol screen.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo group
Placebo soft capsules |
Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
Andre navne:
All subjects will receive diclofenac by IM injection for analgesia as rescue pain control. |
|
Eksperimentel: Study group
PHN131 soft capsule with Nalbuphine Hydrogen chloride (HCl) 60 mg/cap |
All subjects will receive diclofenac by IM injection for analgesia as rescue pain control. Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
the area under the curve of Visual Analogue Scale (VAS) pain intensity scores
Tidsramme: at 1, 2, 3, 4±0.25, 8±0.5, 12±0.5, 16±0.5, 20±0.5, 24±1, 28±1, 32±2, 36±2, 40±2, 44±2, and 48±2 h after the surgery
|
Pain assessment calculated as the area under the curve of VAS pain intensity scores through 48 hours |
at 1, 2, 3, 4±0.25, 8±0.5, 12±0.5, 16±0.5, 20±0.5, 24±1, 28±1, 32±2, 36±2, 40±2, 44±2, and 48±2 h after the surgery
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Consumption of diclofenac dose
Tidsramme: in 48 hours after surgery
|
Consumption of diclofenac (Day 1-2) via Intramuscular Injection (IM injection) |
in 48 hours after surgery
|
|
Time of operation to diclofenac dose
Tidsramme: in 48 hours after surgery
|
Time from the end of operation to the first IM injection diclofenac dose |
in 48 hours after surgery
|
|
Brief Pain Inventory (BPI)
Tidsramme: at 24h and 48h after surgery
|
Brief Pain Inventory (BPI) |
at 24h and 48h after surgery
|
|
Patient satisfaction
Tidsramme: at 48h after surgery
|
Patient satisfaction |
at 48h after surgery
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Chang-Chieh Wu, MD, Tri-Service General Hospital (TSGH)
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PH-CP025
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .